{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:47:29Z","timestamp":1784695649310,"version":"3.55.0"},"reference-count":60,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.7063","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T04:08:09Z","timestamp":1618978089000},"page":"e217063","source":"Crossref","is-referenced-by-count":44,"title":["Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics"],"prefix":"10.1001","volume":"4","author":[{"given":"Tanvee","family":"Varma","sequence":"first","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Wallach","sequence":"additional","affiliation":[{"name":"Department of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Bioethics International, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Schnabel","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Skydel","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey D.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela A.","family":"Dinan","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University, Durham, North Carolina"},{"name":"Duke Cancer Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"},{"name":"Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary P.","family":"Gross","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, Connecticut"},{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"issue":"4","key":"zoi210230r1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/jama.2013.282034","article-title":"Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.","volume":"311","author":"Downing","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"zoi210230r2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","article-title":"Increasing diversity in clinical trials: overcoming critical barriers.","volume":"44","author":"Clark","year":"2019","journal-title":"Curr Probl Cardiol"},{"issue":"10","key":"zoi210230r3","doi-asserted-by":"publisher","first-page":"e191870","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018.","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"zoi210230r4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1089\/jwh.2016.6272","article-title":"Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.","volume":"27","author":"Chen","year":"2018","journal-title":"J Womens Health (Larchmt)"},{"key":"zoi210230r5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13063-016-1322-4","article-title":"Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.","volume":"17","author":"Downing","year":"2016","journal-title":"Trials"},{"issue":"22","key":"zoi210230r6","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities.","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"zoi210230r10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4103\/jfmpc.jfmpc_578_19","article-title":"Trends in FDA drug approvals over last 2 decades: an observational study.","volume":"9","author":"Batta","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"zoi210230r11","doi-asserted-by":"publisher","first-page":"h4633","DOI":"10.1136\/bmj.h4633","article-title":"Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.","volume":"351","author":"Kesselheim","year":"2015","journal-title":"BMJ"},{"issue":"8","key":"zoi210230r12","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamainternmed.2020.2250","article-title":"Limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration.","volume":"180","author":"Hilal","year":"2020","journal-title":"JAMA Intern Med"},{"key":"zoi210230r14","doi-asserted-by":"publisher","first-page":"k2031","DOI":"10.1136\/bmj.k2031","article-title":"Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.","volume":"361","author":"Wallach","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"zoi210230r15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12916-019-1344-3","article-title":"Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.","volume":"17","author":"Wallach","year":"2019","journal-title":"BMC Med"},{"key":"zoi210230r19","doi-asserted-by":"publisher","first-page":"i637","DOI":"10.1136\/bmj.i637","article-title":"Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers.","volume":"352","author":"Chen","year":"2016","journal-title":"BMJ"},{"issue":"7","key":"zoi210230r21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1089\/jwh.2012.3753","article-title":"Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.","volume":"22","author":"Poon","year":"2013","journal-title":"J Womens Health (Larchmt)"},{"key":"zoi210230r24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2162-3619-3-20","article-title":"Neuroblastoma of the elderly, an oncologist\u2019s nightmare: case presentation, literature review and SEER database analysis.","volume":"3","author":"Rogowitz","year":"2014","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"zoi210230r27","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00520-014-2171-x","article-title":"Prevalence and factors associated with polypharmacy in older people with cancer.","volume":"22","author":"Turner","year":"2014","journal-title":"Support Care Cancer"},{"key":"zoi210230r28","doi-asserted-by":"crossref","DOI":"10.5888\/pcd10.120137","article-title":"Prevalence of multiple chronic conditions among Medicare beneficiaries, United States, 2010.","volume":"10","author":"Lochner","year":"2013","journal-title":"Prev Chronic Dis"},{"issue":"2","key":"zoi210230r29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/jgs.15786","article-title":"Adequacy of inclusion of older adults in NIH-funded phase III clinical trials.","volume":"67","author":"Lockett","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"zoi210230r30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041601","article-title":"Informing evidence-based decision-making for patients with comorbidity: availability of necessary information in clinical trials for chronic diseases.","volume":"7","author":"Boyd","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"zoi210230r32","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015594","article-title":"Ten-Year trends in enrollment of women and minorities in pivotal trials supporting recent US Food and Drug Administration approval of novel cardiometabolic drugs.","volume":"9","author":"Khan","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"zoi210230r33","doi-asserted-by":"publisher","first-page":"a034","DOI":"10.1093\/jncics\/pkaa034","article-title":"Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies.","volume":"4","author":"Unger","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"zoi210230r34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cct.2013.03.007","article-title":"A systematic review of the factors influencing African Americans\u2019 participation in cancer clinical trials.","volume":"35","author":"Rivers","year":"2013","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"zoi210230r35","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1200\/JCO.2004.03.160","article-title":"Enrollment of African Americans onto clinical treatment trials: study design barriers.","volume":"22","author":"Adams-Campbell","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi210230r36","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/FCH.0b013e3181ab3bbb","article-title":"Knowledge, attitudes, and practices of underserved women in the rural South toward breast cancer prevention and detection.","volume":"32","author":"Avis-Williams","year":"2009","journal-title":"Fam Community Health"},{"issue":"3","key":"zoi210230r37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/13557851003624281","article-title":"Predictors of awareness of clinical trials and feelings about the use of medical information for research in a nationally representative US sample.","volume":"15","author":"Brown","year":"2010","journal-title":"Ethn Health"},{"issue":"2","key":"zoi210230r38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s13187-011-0300-5","article-title":"The role of health literacy on African American and Hispanic\/Latino perspectives on cancer clinical trials.","volume":"27","author":"Evans","year":"2012","journal-title":"J Cancer Educ"},{"issue":"1","key":"zoi210230r39","first-page":"68","article-title":"Perceptions of participation in an observational epidemiologic study of cancer among African Americans.","volume":"15","author":"Gooden","year":"2005","journal-title":"Ethn Dis"},{"issue":"12","key":"zoi210230r40","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2105\/AJPH.2011.300279","article-title":"Challenging assumptions about minority participation in US clinical research.","volume":"101","author":"Fisher","year":"2011","journal-title":"Am J Public Health"},{"issue":"3","key":"zoi210230r42","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1353\/hpu.0.0323","article-title":"More than Tuskegee: understanding mistrust about research participation.","volume":"21","author":"Scharff","year":"2010","journal-title":"J Health Care Poor Underserved"},{"issue":"5","key":"zoi210230r43","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/hex.2015.18.issue-5","article-title":"A disparity of words: racial differences in oncologist-patient communication about clinical trials.","volume":"18","author":"Eggly","year":"2015","journal-title":"Health Expect"},{"issue":"3","key":"zoi210230r44","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0027-9684(15)31241-4","article-title":"Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.","volume":"100","author":"Pinsky","year":"2008","journal-title":"J Natl Med Assoc"},{"issue":"9","key":"zoi210230r45","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/cncr.32755","article-title":"Bias and stereotyping among research and clinical professionals: perspectives on minority recruitment for oncology clinical trials.","volume":"126","author":"Niranjan","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"zoi210230r46","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/MJT.0000000000000177","article-title":"Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.","volume":"22","author":"Eshera","year":"2015","journal-title":"Am J Ther"},{"issue":"8","key":"zoi210230r47","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/S1047-2797(00)00198-8","article-title":"Representation of Asian Americans in clinical cancer trials.","volume":"10","author":"Alexander","year":"2000","journal-title":"Ann Epidemiol"},{"issue":"12","key":"zoi210230r48","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Asian Americans and cancer clinical trials: a mixed-methods approach to understanding awareness and experience.","volume":"104","author":"Paterniti","year":"2005","journal-title":"Cancer"},{"issue":"32","key":"zoi210230r51","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1200\/JCO.2015.63.0319","article-title":"Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement.","volume":"33","author":"Hurria","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi210230r53","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1468-0009.2011.00636.x","article-title":"An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences.","volume":"89","author":"Kesselheim","year":"2011","journal-title":"Milbank Q"},{"issue":"1","key":"zoi210230r54","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1634\/theoncologist.2017-0687","article-title":"Characterization of comorbidities limiting the recruitment of patients in early phase clinical trials.","volume":"24","author":"Duma","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"zoi210230r55","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","article-title":"Association of patient comorbid conditions with cancer clinical trial participation.","volume":"5","author":"Unger","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"zoi210230r56","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/cts.12285","article-title":"Culturally competent strategies for recruitment and retention of African American populations into clinical trials.","volume":"8","author":"Otado","year":"2015","journal-title":"Clin Transl Sci"},{"issue":"4","key":"zoi210230r57","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/107327481602300404","article-title":"Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer.","volume":"23","author":"Hamel","year":"2016","journal-title":"Cancer Control"},{"issue":"2","key":"zoi210230r58","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/1740774519887148","article-title":"Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews.","volume":"17","author":"Liu","year":"2020","journal-title":"Clin Trials"},{"issue":"11","key":"zoi210230r59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143515","article-title":"Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology\u2014mainland China subset analysis of the PIONEER study.","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"zoi210230r60","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).","volume":"5","author":"Midha","year":"2015","journal-title":"Am J Cancer Res"},{"key":"zoi210230r41","volume-title":"Washington. Medical Apartheid: The Dark History of Medical Experimentation on Black Americans from Colonial Times to the Present","author":"Harriet","year":"2006"},{"key":"zoi210230r50"},{"key":"zoi210230r7","unstructured":"U.S. Food and Drug Administration. Evaluation and reporting of age-, race- and ethnicity-specific data in medical device clinical studies. Accessed July 23, 2020. https:\/\/www.fda.gov\/media\/98686\/download"},{"key":"zoi210230r8","unstructured":"Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research. Enhancing the diversity of clinical trial populations\u2014eligibility criteria, enrollment practices, and trial designs: guidance for industry. US Food and Drug Administration. Accessed November 9, 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial"},{"key":"zoi210230r9","unstructured":"US Food and Drug Administration. FDA Action Plan to Enhance Collection and Availability of Demographic subgroup data. Accessed July 23, 2020. https:\/\/www.fda.gov\/media\/89307\/download"},{"key":"zoi210230r13","unstructured":"FDA in brief: FDA affirms commitment to postmarket study requirements; warns company for failure to submit final postmarket study report. US Food and Drug Administration. Accessed October 26, 2020. https:\/\/www.fda.gov\/news-events\/fda-brief\/fda-brief-fda-affirms-commitment-postmarket-study-requirements-warns-company-failure-submit-final"},{"key":"zoi210230r16","doi-asserted-by":"crossref","unstructured":"Skydel? JJ, Zhang? AD, Dhruva? SS, Ross? JS, Wallach? JD. U.S.? Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.? medRxiv. Published online September 2, 2020:2020.08.31.20184184. doi:10.1101\/2020.08.31.20184184","DOI":"10.1101\/2020.08.31.20184184"},{"key":"zoi210230r17","unstructured":"Compilation of CDER new molecular entity (NME) drug and new biologic approvals. US Food and Drug Administration. Accessed July 15, 2020. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals"},{"key":"zoi210230r18","unstructured":"Drugs@FDA: FDA-approved drugs. US Food and Drug Administration. Accessed March 26, 2021. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/"},{"key":"zoi210230r20","unstructured":"United States cancer statistics. US Centers for Disease Control and Prevention. Accessed July 15, 2020. https:\/\/www.cdc.gov\/cancer\/uscs\/index.htm"},{"key":"zoi210230r22","unstructured":"Lane? DM. Proportion. OnlineStatBook.com. Accessed August 30, 2020. https:\/\/onlinestatbook.com\/2\/estimation\/proportion_ci.html"},{"key":"zoi210230r23","unstructured":"Centers for Disease Control and Prevention. Cancer stat facts: soft tissue including heart cancer. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Accessed July 21, 2020. https:\/\/seer.cancer.gov\/statfacts\/html\/soft.html"},{"key":"zoi210230r25","unstructured":"National Cancer Institute. Age and cancer risk. Accessed February 19, 2021. https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/age"},{"key":"zoi210230r26","unstructured":"FDA in brief: FDA encourages inclusion of older adult patients in cancer clinical trials. US Food and Drug Administration. Accessed July 21, 2020. https:\/\/www.fda.gov\/news-events\/fda-brief\/fda-brief-fda-encourages-inclusion-older-adult-patients-cancer-clinical-trials"},{"key":"zoi210230r31","unstructured":"Oncology Center of Excellence, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Inclusion of older adults in cancer clinical trials. US Food and Drug Administration. Accessed October 6, 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/inclusion-older-adults-cancer-clinical-trials"},{"key":"zoi210230r49","unstructured":"Center for Drug Evaluation and Research, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research, Office of the Commissioner Office of Minority Health and Health Equity, Office of the Commissioner Office of Women's Health. Collection of race and ethnicity data in clinical trials. US Food and Drug Administration. Accessed August 27, 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/collection-race-and-ethnicity-data-clinical-trials"},{"key":"zoi210230r52","doi-asserted-by":"crossref","unstructured":"Levit? L, Balogh? E, Nass? S, Ganz? P. Delivering high-quality cancer care: charting a new course for a system in crisis. Institute of Medicine of the National Academies. Accessed October 14, 2020. https:\/\/commed.vcu.edu\/Chronic_Disease\/Cancers\/2014\/CancerCare2013_IOM.pdf","DOI":"10.17226\/18359"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2778908\/varma_2021_oi_210230_1620402834.91568.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T15:01:58Z","timestamp":1621350118000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2778908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.7063","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}